Cargando…
Anticancer Activity of Novel NF-κB Inhibitor DHMEQ by Intraperitoneal Administration
There have been great advances in the therapy of cancer and leukemia. However, there are still many neoplastic diseases that are difficult to treat. For example, it is often difficult to find effective therapies for aggressive cancer and leukemia. An NF-κB inhibitor named dehydroxymethylepoxyquinomi...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cognizant Communication Corporation
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7751220/ https://www.ncbi.nlm.nih.gov/pubmed/32576339 http://dx.doi.org/10.3727/096504020X15929100013698 |
_version_ | 1783625624015863808 |
---|---|
author | Umezawa, Kazuo Breborowicz, Andrzej Gantsev, Shamil |
author_facet | Umezawa, Kazuo Breborowicz, Andrzej Gantsev, Shamil |
author_sort | Umezawa, Kazuo |
collection | PubMed |
description | There have been great advances in the therapy of cancer and leukemia. However, there are still many neoplastic diseases that are difficult to treat. For example, it is often difficult to find effective therapies for aggressive cancer and leukemia. An NF-κB inhibitor named dehydroxymethylepoxyquinomicin (DHMEQ) was discovered in 2000. This compound was designed based on the structure of epoxyquinomicin isolated from a microorganism. It was shown to be a specific inhibitor that directly binds to and inactivates NF-κB components. Until now, DHMEQ has been used by many scientists in the world to suppress animal models of cancer and inflammation. Especially, it was shown to suppress difficult cancer models, such as hormone-insensitive breast cancer and prostate cancer, cholangiocarcinoma, and multiple myeloma. No toxicity has been reported so far. DHMEQ was administered via the intraperitoneal (IP) route in most of the animal experiments because of its simplicity. In the course of developmental studies, it was found that IP administration never increased the blood concentration of DHMEQ because of the instability of DHMEQ in the blood. It is suggested that inflammatory cells in the peritoneal cavity would be important for cancer progression, and that IP administration, itself, is important for the effectiveness and safety of DHMEQ. In the present review, we describe mechanism of action, its in vivo anticancer activity, and future clinical use of DHMEQ IP therapy. |
format | Online Article Text |
id | pubmed-7751220 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Cognizant Communication Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-77512202021-02-16 Anticancer Activity of Novel NF-κB Inhibitor DHMEQ by Intraperitoneal Administration Umezawa, Kazuo Breborowicz, Andrzej Gantsev, Shamil Oncol Res Review There have been great advances in the therapy of cancer and leukemia. However, there are still many neoplastic diseases that are difficult to treat. For example, it is often difficult to find effective therapies for aggressive cancer and leukemia. An NF-κB inhibitor named dehydroxymethylepoxyquinomicin (DHMEQ) was discovered in 2000. This compound was designed based on the structure of epoxyquinomicin isolated from a microorganism. It was shown to be a specific inhibitor that directly binds to and inactivates NF-κB components. Until now, DHMEQ has been used by many scientists in the world to suppress animal models of cancer and inflammation. Especially, it was shown to suppress difficult cancer models, such as hormone-insensitive breast cancer and prostate cancer, cholangiocarcinoma, and multiple myeloma. No toxicity has been reported so far. DHMEQ was administered via the intraperitoneal (IP) route in most of the animal experiments because of its simplicity. In the course of developmental studies, it was found that IP administration never increased the blood concentration of DHMEQ because of the instability of DHMEQ in the blood. It is suggested that inflammatory cells in the peritoneal cavity would be important for cancer progression, and that IP administration, itself, is important for the effectiveness and safety of DHMEQ. In the present review, we describe mechanism of action, its in vivo anticancer activity, and future clinical use of DHMEQ IP therapy. Cognizant Communication Corporation 2020-12-10 /pmc/articles/PMC7751220/ /pubmed/32576339 http://dx.doi.org/10.3727/096504020X15929100013698 Text en Copyright © 2020 Cognizant, LLC. http://creativecommons.org/licenses/by-nc-nd/4.0/ This article is licensed under a Creative Commons Attribution-NonCommercial NoDerivatives 4.0 International License. |
spellingShingle | Review Umezawa, Kazuo Breborowicz, Andrzej Gantsev, Shamil Anticancer Activity of Novel NF-κB Inhibitor DHMEQ by Intraperitoneal Administration |
title | Anticancer Activity of Novel NF-κB Inhibitor DHMEQ by Intraperitoneal Administration |
title_full | Anticancer Activity of Novel NF-κB Inhibitor DHMEQ by Intraperitoneal Administration |
title_fullStr | Anticancer Activity of Novel NF-κB Inhibitor DHMEQ by Intraperitoneal Administration |
title_full_unstemmed | Anticancer Activity of Novel NF-κB Inhibitor DHMEQ by Intraperitoneal Administration |
title_short | Anticancer Activity of Novel NF-κB Inhibitor DHMEQ by Intraperitoneal Administration |
title_sort | anticancer activity of novel nf-κb inhibitor dhmeq by intraperitoneal administration |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7751220/ https://www.ncbi.nlm.nih.gov/pubmed/32576339 http://dx.doi.org/10.3727/096504020X15929100013698 |
work_keys_str_mv | AT umezawakazuo anticanceractivityofnovelnfkbinhibitordhmeqbyintraperitonealadministration AT breborowiczandrzej anticanceractivityofnovelnfkbinhibitordhmeqbyintraperitonealadministration AT gantsevshamil anticanceractivityofnovelnfkbinhibitordhmeqbyintraperitonealadministration |